Over the last 12 months, two Alamar Biosciences, Inc. company insiders bought shares with their own money, about $8 million in total, and none of them sold.
Illumina Innovation Fund II GP, L.L.C. (10% Owner) made the biggest buy, worth around $4 million.
Big money check: 86 institutions held ALMR as of Q2 2026, and more funds bought than sold. Zooming out by quarter: No open-market insider buying or selling in the last full quarter. Insiders bought in 1 of the last 7 full quarters.
| Filed | Insider | Role | Type | Shares | Price | Value | Source |
|---|---|---|---|---|---|---|---|
| Apr 20, 2026 | Illumina Innovation Fund II GP, L.L.C. | 10% Owner | Buy | 235,294 | $17.00 | $4.0M | SEC |
| Apr 20, 2026 | Naclerio Nicholas | Director | Buy | 235,294 | $17.00 | $4.0M | SEC |
In the last 12 months Alamar Biosciences, Inc. insiders made open-market purchases worth about $8 million and sales worth about $0. Data comes from SEC Form 4 filings, updated every 30 minutes on CapitalSnitch.
The most recent open-market insider trade in ALMR was filed on 2026-04-20.
86 investment managers reported holding ALMR in SEC Form 13F filings for Q2 2026.
No congressional trades in ALMR were reported in the past two years. The full list is free on CapitalSnitch.
Public-record data for research and education, not investment advice. Insider sales are often pre-planned (10b5-1). Congress data: Data derived from public disclosures filed under the Ethics in Government Act and the STOCK Act, republished free for public transparency and news reporting. Disclosures may lag the trade by 45 days or more and show amounts only as ranges. This data may not be used for credit rating, loan underwriting, solicitation of money (political, charitable or other), direct-mail or commercial targeting (5 U.S.C. 13107).